A meta-analysis of 28 studies has found that use of poly (ADP-ribose) polymerase (PARP) inhibitors increases the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), compared with placebo and other treatments.
However, these complications, although concerning, remain uncommon, with less than 1% of PARP inhibitor recipients developing MDS or AML.
“Myelodysplastic syndrome and acute myeloid leukemia cases related to PARP inhibitor therapy appear to be rare and